Literature DB >> 3488019

In vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) against clinical isolates of Haemophilus influenzae.

J H Jorgensen, J S Redding, A W Howell.   

Abstract

The in vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) was compared with the activities of five other orally absorbable antimicrobial agents against 100 clinical isolates of Haemophilus influenzae. Roxithromycin MICs were generally twofold to fourfold higher than those of erythromycin; the MIC for 90% of the strains for roxithromycin was 8 micrograms/ml.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3488019      PMCID： PMC284180          DOI： 10.1128/AAC.29.5.921

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Erythromycin concentrations in middle ear exudates.

Authors:  J W Bass; R W Steele; R A Wiebe; E P Dierdorff
Journal:  Pediatrics       Date:  1971-09       Impact factor: 7.124

2.  Concentrations of antimicrobial agents in middle ear fluid, saliva and tears.

Authors:  J D Nelson; C M Ginsburg; O Mcleland; J Clahsen; M C Culbertson; H Carder
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1981-12       Impact factor: 1.675

3.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

4.  In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

5.  Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.

Authors:  H Goossens; P De Mol; H Coignau; J Levy; O Grados; G Ghysels; H Innocent; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

6.  Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli.

Authors:  V Lorian; L D Sabath
Journal:  Appl Microbiol       Date:  1970-11

7.  Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media.

Authors:  P J Krause; N J Owens; C H Nightingale; J J Klimek; W B Lehmann; R Quintiliani
Journal:  J Infect Dis       Date:  1982-06       Impact factor: 5.226
  7 in total
  8 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  Concentrations of roxithromycin (RU 28965) in serum and in sinus mucosa.

Authors:  A Kropec; E Schmidt-Eisenlohr; F D Daschner
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

4.  In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

5.  Roxithromycin bioassay procedures for human plasma, urine and milk specimens [corrected and issued with original paging in Eur J Clin Microbiol 1986 Dec;5(6)].

Authors:  A L Barry; R R Packer
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

6.  Pharmacokinetics and tissue penetration of roxithromycin after multiple dosing.

Authors:  R Wise; B Kirkpatrick; J Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

7.  Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model.

Authors:  P B Fernandes; D Hardy; R Bailer; E McDonald; J Pintar; N Ramer; R Swanson; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

Review 8.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.